Novofen (Tamoxifen)

Tamoxifen binds to estrogen receptors in breast tissue, acting as an antagonist that blocks estrogen‑driven cell growth. In bone and uterine tissue it shows partial agonist activity, preserving bone density while still inhibiting tumor proliferation. Its active metabolites, produced mainly by CYP2D6, sustain this anti‑estrogenic effect.

The specific dose of Novofen is determined by the prescribing clinician based on the individual’s medical condition, treatment stage, and response. Standard dosing regimens for tamoxifen exist, but the exact amount and schedule should be set by a qualified healthcare professional.

Novofen is classified as Pregnancy Category D, indicating evidence of risk to the fetus. It should not be used during pregnancy, and women of child‑bearing potential must use effective contraception. Breastfeeding is not recommended while taking tamoxifen because the drug can pass into milk.

To order Novofen, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details, and any necessary import documentation.

The primary alternative to tamoxifen is the class of aromatase inhibitors, which lower estrogen production rather than blocking its receptor. Aromatase inhibitors are often used in post‑menopausal women, whereas tamoxifen is effective in both pre‑ and post‑menopausal patients and also offers bone‑protective benefits.

Novofen tablets should be stored at room temperature, below 25 °C, in the original packaging to protect them from moisture and excessive heat. Keep the container tightly closed and out of direct sunlight to maintain product stability.

Novofen is taken orally as a tablet, usually with a glass of water. It can be taken with or without food, but consistency with meals may help reduce gastrointestinal upset. Patients should follow the dosing schedule prescribed by their healthcare provider.

Serious risks include blood clots such as deep vein thrombosis or pulmonary embolism, endometrial cancer, severe liver injury, and cerebrovascular events like stroke. Patients should promptly report symptoms such as unexplained leg swelling, abnormal uterine bleeding, jaundice, or sudden neurological changes.

Novofen should not be used by pregnant women, individuals with a known history of thromboembolic disease, patients with active or past endometrial cancer, and those with severe liver impairment. Contra‑indications are determined by the prescribing clinician based on the patient’s overall health profile.